Onesource Specialty Pharma
add_icon

Onesource Specialty Pharma

1,469.20
-4.40
(-0.30%)
Market Cap
16,834.85 Cr
PE Ratio
846.46
Volume
1,67,736.00
Day High - Low
1,494.90 - 1,420.00
52W High-Low
2,248.00 - 1,057.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
16,834.85 Cr
EPS
-1.63
PE Ratio
846.46
PB Ratio
2.88
Book Value
515.13
EBITDA
484.00
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
-0.29
Debt to Equity
0.21
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+75.00 %
+75.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell+25.00 %
+25.00 %
Forecast For
Actual

Company News

View All News
Caret
neutral
OneSource Specialty Pharma's board decides to conduct additional review before filing NCLT application for composite scheme involving Steriscience facilities acquisition.
neutral
OneSource Specialty Pharma Limited has withdrawn its credit ratings from CareEdge Ratings as part of periodic review and rationalisation, while maintaining IND A- Positive rating from India Ratings.
neutral
OneSource Specialty Pharma Limited will participate in Investec India Promoter & Founder Conference 2026 on March 09, 2026 in Mumbai for investor engagement activities.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,825.30
#1 4,37,950.61
39.98
#1 54,729.00
9.71
#1 10,980
16.07
70.29
6,282.00
1,66,767.36
67.99
9,712.00
18.67
2,191
-1.02
49.00
4,446.00
1,50,472.84
65.98
11,539.40
6.99
1,911
26.24
68.79
1,319.00
1,10,087.74
20.03
33,741.20
16.73
5,725
-15.28
59.78
2,357.30
1,07,681.18
22.96
22,909.50
13.74
3,306
#1 37.44
67.87
1,324.30
1,06,973.22
23.70
28,409.50
7.12
5,291
-57.18
43.23
916.90
92,261.59
#1 18.46
23,511.00
18.55
4,615
-0.32
52.66
2,207.90
91,143.23
51.36
12,744.20
#1 20.90
2,007
7.65
55.18
1,311.90
76,195.36
21.74
32,345.60
9.43
3,484
7.59
70.43
5,444.00
65,091.19
27.32
13,458.30
3.70
2,216
1.90
43.98
Growth Rate
Revenue Growth
730.38 %
Net Income Growth
-95.27 %
Cash Flow Change
36.71 %
ROE
-99.69 %
ROCE
-103.78 %
EBITDA Margin (Avg.)
-169.39 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
10
34
88
76
296
338
399
429
333
379
295
Expenses
80
105
173
76
233
263
351
244
242
269
280
EBITDA
-70
-71
-85
-0
64
76
48
185
91
110
15
Operating Profit %
-800 %
-210 %
-207 %
-4 %
20 %
21 %
11 %
43 %
26 %
28 %
4 %
Depreciation
19
18
20
20
68
68
69
69
68
70
70
Interest
18
25
26
21
42
45
46
33
28
34
38
Profit Before Tax
-107
-114
-130
-40
-47
-38
-67
83
-4
6
-93
Tax
0
0
0
0
-41
5
2
-16
-4
-5
-4
Net Profit
-107
-114
-130
-40
-6
-42
-69
99
-0
11
-89
EPS in ₹
0.00
-27.37
-31.32
-9.67
-0.51
-10.13
-6.31
8.61
-0.02
0.92
-7.74

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
972
1,258
2,442
2,009
1,309
7,550
Fixed Assets
354
633
1,231
1,361
863
6,118
Current Assets
25
99
511
228
176
1,086
Capital Work in Progress
543
431
490
335
188
218
Investments
0
0
0
5
20
16
Other Assets
75
195
722
309
238
1,199
Total Equity & Liabilities
972
1,258
2,442
2,009
1,309
7,550
Current Liabilities
194
161
809
865
631
1,114
Non Current Liabilities
361
321
621
358
282
556
Total Equity
417
776
1,013
786
396
5,881
Reserve & Surplus
414
775
1,009
781
392
5,869
Share Capital
1
2
3
4
4
11

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
56
55
-112
13
143
Investing Activities
-207
-692
-68
511
-201
Operating Activities
-118
-416
-163
-107
-68
Financing Activities
381
1,162
118
-391
412

Share Holding

% Holding
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
37.77 %
34.25 %
29.79 %
29.77 %
29.93 %
FIIs
17.44 %
18.54 %
18.69 %
19.39 %
19.24 %
DIIs
12.56 %
18.04 %
18.10 %
18.49 %
18.81 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
13.05 %
12.50 %
13.25 %
12.42 %
12.39 %
Others
19.18 %
16.67 %
20.17 %
19.93 %
19.63 %
No of Share Holders
98,425
82,712
87,760
87,416
84,595

Announcements

Update On Composite Scheme Of Arrangement5 days ago
Announcement under Regulation 30 (LODR)-Credit Rating6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Intimation Regarding Receipt Of No Objection/ No Adverse Observation Letter From The National Stock Exchange Of India Limited / BSE Limited In Realation To The Draft Composite Scheme Of Arrangement And Amalgamation (Merger By Absorption).Feb 26, 2026
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 12, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2026
Onesource Specialty Pharma Limited Has Informed The Exchange Regarding Disclosure Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares & Takeovers)Regulations 2011 And Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2Feb 04, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2026
Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations 2011 And Regulation 7(2) Of SEBI (PIT) Regulations 2015Jan 28, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 28, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 25, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jan 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jan 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 23, 2026
Board Meeting Outcome for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended December 31 2025Jan 23, 2026
Allotment Of Equity Shares Under The Onesource Specialty Pharma Limited - Employee Stock Option Plan - 2021Jan 21, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 19, 2026
Board Meeting Intimation for Intimation Of The Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 For Approval Of Unaudited Financial Results Of The Company For The Quarter Ended December 31 2Jan 19, 2026
Corporate Action-Amalgamation/ Merger / DemergerJan 14, 2026
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 09, 2026
Intimation Of The Press Release Of Credit Rating Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015Dec 31, 2025
Closure of Trading WindowDec 24, 2025
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Dec 23, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Dec 19, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 11, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 18, 2025
Update On Non-Participation Of The Representatives Of The Company In The Jefferies ConferenceNov 18, 2025
General UpdatesNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Investor PresentationNov 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 11, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 11/11/2025 To Approve The Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Board Meeting Intimation for Approving The Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 05, 2025
Investor PresentationSep 26, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementSep 26, 2025
Closure of Trading WindowSep 26, 2025
Voting Results Of The Annual General Meeting Held On 22Nd September 2025Sep 24, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 22, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Healthcare Fund Direct - Growth
1.14%
2500
0.18%
-0.08%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.39%
650
0.04%
-0.11%
JioBlackRock Sector Rotation Fund Direct - Growth
0.04%
308
0.04%
0.04%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.39%
27
0.04%
-0.11%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.13%
-13
0.01%
-0.04%
DSP Nifty 500 Index Fund Direct-Growth
0.04%
-2
0.01%
0.04%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.04%
1
0.00%
-0.01%
LIC MF Healthcare Fund Direct - Growth
3.63%
0
0.00%
0.80%
Mirae Asset Aggressive Hybrid Fund Direct-Growth
0.44%
0
0.00%
0.04%
Angel One Nifty Total Market Index Fund Direct - Growth
0.04%
0
0.00%
0.00%
Axis Business Cycles Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Equity Savings Fund Direct-Growth
0.11%
0
0.00%
0.01%
Axis ESG Integration Strategy Fund Direct-Growth
1.20%
0
0.00%
1.20%
Axis Flexi Cap Fund Direct-Growth
0.68%
0
0.00%
0.07%
Axis India Manufacturing Fund Direct-Growth
0.01%
0
0.00%
0.00%
Axis Nifty 500 Index Fund Direct-Growth
0.04%
0
0.00%
0.00%
Axis Small Cap Fund Direct-Growth
0.47%
0
0.00%
0.00%
Axis Value Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.53%
0
0.00%
0.03%
Bandhan Midcap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.39%
0
0.00%
0.04%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.04%
0
0.00%
0.01%
Bandhan Small Cap Fund Direct-Growth
0.27%
0
0.00%
0.02%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.39%
0
0.00%
0.04%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.39%
0
0.00%
0.04%

Technical Indicators

RSI(14)
Neutral
60.52
ATR(14)
Less Volatile
81.31
STOCH(9,6)
Overbought
86.82
STOCH RSI(14)
Overbought
84.82
MACD(12,26)
Bullish
32.30
ADX(14)
Strong Trend
27.72
UO(9)
Bearish
70.37
ROC(12)
Uptrend And Accelerating
16.06
WillR(14)
Neutral
-20.66